Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
710
¥ million (year-on-year change in net sales)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFiscal year ending March 202611 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥33,942 million+2.1%
Operating profit¥1,439 million-7.8%
Ordinary income¥1,406 million+5.5%
Net income¥1,135 million +4.0%net income attributable to owners of the parent
Gross Profit Margin44.8%
Operating profit margin4.2%
Selling, general and administrative expenses¥13,782 million
Full-year earnings forecast
Net Sales
¥37,000 million
Operating profit
¥2,200 million
Ordinary income
¥1,750 million
Net income
¥1,350 million net income attributable to owners of the parent
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales91.7%
Operating profit72.0%
Ordinary income87.9%
Net income103.2%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in gross profit+¥594 million
- Increase in selling, general and administrative expenses-¥716 million
- Increase in non-operating income+¥219 million
- Increase in non-operating expenses-¥24 million
- Increase in extraordinary income+¥77 million
- Decrease in extraordinary losses+¥10 million
- Increase in taxes and other items-¥116 million
New initiatives
- Expansion of production capacity at Building 4 of the Konosu Research Institute
- Launch of 2 new colors for the Belmi line
- Rebranding of the Pure series
- Company split of the smart contact lens business
- Establishment of a China Sales Department
- Development of next-generation products, including silicone hydrogel lenses and specialty lenses
Key KPIsA metric the company considers important as a management benchmark.
- Overseas revenue¥53.6 100 millionYear on year against the same period last year+5.3%
- Orthokeratology lens revenue¥902 millionYear on year against the same period last year+9.5%
- EBITDA¥5,114 million
- EBITDA margin15.1 %Year on year against the same period last year-0.1 percentage points
- Equity ratio31.2 %Year on year against the same period last year+0.4 percentage points
- ROE6.1 %Year on year against the same period last year-0.1 percentage points
Segment results
Not disclosed (business-category revenue: contact lenses ¥33,258 million, care products ¥590 million, other ¥92 million)Medium-term management plan targets
- Consolidated net salesTarget value370Target fiscal yearFiscal year ending March 2027
- Consolidated operating incomeTarget value22Target fiscal yearFiscal year ending March 2027
- EBITDATarget value69.5Target fiscal yearFiscal year ending March 2027
- ROETarget value6.9Target fiscal yearFiscal year ending March 2027
Financial targets
ROE
Actual results for the fiscal year ending March 20266.1%
Target for the fiscal year ending March 20276.9%
Number of stores and locations
End of period8 sales offices, 11 other locations
Number of employees
Number of Employees1,489 People consolidated, as of the end of March 2026
Capital expenditures
¥3,128 million capital expenditures for the acquisition of property, plant and equipment
Annual Dividend
Annual¥15 per share
Payout ratio
Target: 30–40%; actual for the fiscal year ended March 2026: 40.0%| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | ¥33,942 million (YoY +2.1%) |
| Operating profit | ¥1,439 million (YoY -7.8%) |
| Ordinary income | ¥1,406 million (YoY +5.5%) |
| Net income | ¥1,135 million (net income attributable to owners of the parent) (YoY +4.0%) |
| Gross Profit Margin | 44.8% |
| Operating profit margin | 4.2% |
| Selling, general and administrative expenses | ¥13,782 million |
| Full-year earnings forecast | Net Sales ¥37,000 million / Operating profit ¥2,200 million / Ordinary income ¥1,750 million / Net income ¥1,350 million (net income attributable to owners of the parent) |
| Progress against full-year forecast | Net Sales 91.7% / Operating profit 72.0% / Ordinary income 87.9% / Net income 103.2% |
| Segment results | Not disclosed (business-category revenue: contact lenses ¥33,258 million, care products ¥590 million, other ¥92 million) |
| Breakdown of Factors Affecting the Change | Factors Increase in gross profit / Amount +¥594 million, Factors Increase in selling, general and administrative expenses / Amount -¥716 million, Factors Increase in non-operating income / Amount +¥219 million, Factors Increase in non-operating expenses / Amount -¥24 million, Factors Increase in extraordinary income / Amount +¥77 million, Factors Decrease in extraordinary losses / Amount +¥10 million, Factors Increase in taxes and other items / Amount -¥116 million |
| Key KPIs | Indicator name Overseas revenue / Value ¥53.6 100 million / Year on year against the same period last year +5.3%, Indicator name Orthokeratology lens revenue / Value ¥902 million / Year on year against the same period last year +9.5%, Indicator name EBITDA / Value ¥5,114 million / Year on year against the same period last year Not disclosed, Indicator name EBITDA margin / Value 15.1 % / Year on year against the same period last year -0.1 percentage points, Indicator name Equity ratio / Value 31.2 % / Year on year against the same period last year +0.4 percentage points, Indicator name ROE / Value 6.1 % / Year on year against the same period last year -0.1 percentage points |
| Number of stores and locations | End of period 8 sales offices, 11 other locations / Number of store openings and closures during the period Not disclosed |
| Number of employees | Number of Employees 1,489 People (consolidated, as of the end of March 2026) / Changes during the period and hiring plan Not disclosed |
| Medium-term management plan targets | Indicator Consolidated net sales / Target value ¥370 100 million / Target fiscal year Fiscal year ending March 2027, Indicator Consolidated operating income / Target value ¥22 100 million / Target fiscal year Fiscal year ending March 2027, Indicator EBITDA / Target value ¥69.5 100 million / Target fiscal year Fiscal year ending March 2027, Indicator ROE / Target value 6.9 % / Target fiscal year Fiscal year ending March 2027 |
| Financial targets | ROE Actual results for the fiscal year ending March 2026 6.1% / Target for the fiscal year ending March 2027 6.9% / Equity ratio Not disclosed / Debt-to-equity ratio Not disclosed / Debt dependency ratio Not disclosed |
| Annual Dividend | Annual ¥15 per share / Interim Not disclosed / End of period Not disclosed |
| Payout ratio | Target: 30–40%; actual for the fiscal year ended March 2026: 40.0% |
| Capital expenditures | ¥3,128 million (capital expenditures for the acquisition of property, plant and equipment) |
| New initiatives | Expansion of production capacity at Building 4 of the Konosu Research Institute, Launch of 2 new colors for the Belmi line, Rebranding of the Pure series, Company split of the smart contact lens business, Establishment of a China Sales Department, Development of next-generation products, including silicone hydrogel lenses and specialty lenses |
Items this document does not state (9)
Results for the three months of the current quarterSelf-assessment against the planUnit price and quantity metricsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue grew mainly through the Pure series, but was affected by market price competition and the diversification of distribution channels. Gross profit increased as production issues that occurred in the previous fiscal year were resolved and yields improved, although the weaker yen increased the procurement costs of some imported products. Operating profit declined because selling, general and administrative expenses increased due to the company split of the smart contact lens business, the launch of a logistics hub in Singapore, advisory fees related to consideration of organizational restructuring, and other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.